Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib in BRAF-mutant Metastatic Melanoma
NCT01072175Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of dabrafenib + trametinib and trametinib in melanoma, sponsored by Novartis. Primary endpoints: Maximum Plasma Concentration at Day 21, Area Under the Concentration-time Curve at Day 21 and 4 more. Started Mar 2010; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01072175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01072175.